BARD Score for NAFLD Fibrosis

ورودی‌های بالینی بیمار

حداقل ۱۰ — حداکثر ۷۰ • واحد: kg/m²

حداقل ۱ — حداکثر ۵۰۰۰ • واحد: U/L

حداقل ۱ — حداکثر ۵۰۰۰ • واحد: U/L

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
bard score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–1
  • High Risk2–4
Direct Clinical Answer

The BARD Score for NAFLD Fibrosis calculates predicting risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Key inputs include bmi. Scores guide managing portal hypertension complications, referring for liver transplant evaluation, and supportive care. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Predicts risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The BARD score uses three simple clinical parameters (BMI, AST/ALT ratio, and diabetes) to identify patients at low risk of advanced fibrosis who may not require liver biopsy.

Clinical Indication

The BARD Score for NAFLD Fibrosis is indicated for bedside clinical practice to support Predicts risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The BARD score uses three simple clinical parameters (BMI, AST/ALT ratio, and diabetes) to identify patients at low risk of advanced fibrosis who may not require liver biopsy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with decompensated liver cirrhosis, acute liver failure, portal hypertension, ascites, or end-stage liver disease awaiting organ allocation. Clinical application is indicated across Hepatology clinics, liver transplant assessment centers, gastroenterology wards, and liver ICUs.

Limitations & Contraindications

Due to muscle wasting and reduced hepatic creatine synthesis, serum creatinine routinely underestimates renal dysfunction in cirrhosis.

Clinical Pearls & Action Plan

Preventing spontaneous bacterial peritonitis (SBP), managing variceal hemorrhage, and monitoring hepatic encephalopathy are top clinical priorities.

Formula & Variables:

BARD Score = BMI ≥28 (1 point) + AST/ALT ratio ≥0.8 (2 points) + Diabetes (1 point)

Input Parameters

NameTypeRequiredDescription
bmifloatYesBody Mass Index (weight in kg / height in m²)(kg/m²)
astfloatYesAspartate aminotransferase (AST)(U/L)
altfloatYesAlanine aminotransferase (ALT)(U/L)
diabetesstringYesPresence of type 2 diabetes mellitus

Score Interpretation & Guidance

RangeStageDescription
0–1Low RiskLow risk of advanced fibrosis
2–4High RiskHigh risk of advanced fibrosis

Evidence-Based References (EBM)

  • Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008 Oct;57(10):1441-7. doi: 10.1136/gut.2007.146019.DOI: 10.1136/gut.2007.146019
  • Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010 Jun 17;10:67. doi: 10.1186/1471-230X-10-67.DOI: 10.1186/1471-230X-10-67
  • Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012 Dec;18(12):CR735-40. doi: 10.12659/msm.883601.DOI: 10.12659/msm.883601

Related calculators